Efficacy of inebilizumab in N-MOmentum trial participants with or without prior immunosuppressants

Tools

Preview	PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader 946kB
	MS Word (Supporting Information) 78kB

Item Type:	Article
Title:	Efficacy of inebilizumab in N-MOmentum trial participants with or without prior immunosuppressants
Creators Name:	Cree, Bruce A.C., Suero, Beatrice, Walsh, Sarah, Marignier, Romain, Lindsey, John W., Kim, Ho Jin, She, Dewei, Cimbora, Daniel, Cavida, Dustin and Paul, Friedemann
Abstract:	This post hoc analysis examined the impact of prior immunosuppressants on the long-term efficacy and safety of inebilizumab, a cluster of differentiation 19 B-cell-depleting monoclonal antibody, in participants with aquaporin-4-seropositive neuromyelitis optica spectrum disorder from the N-MOmentum trial (NTC02200770). Inebilizumab treatment resulted in a sustained low annualized attack rate relative to the pretrial annualized attack rate and a high probability of remaining attack-free for up to 4 years among participants with and without prior immunosuppressant use. Based on modeling data, inebilizumab had greater long-term efficacy than historical immunosuppressants. Inebilizumab was well tolerated regardless of prior immunosuppressant use.
Keywords:	Aquaporin- 4 (AQP4), Inebilizumab, Long-Term Management, Neuromyelitis Optica Spectrum Disorder (NMOSD), Prior Immunosuppression
Source:	Annals of Clinical and Translational Neurology
ISSN:	2328-9503
Publisher:	Wiley
Date:	12 May 2026
Official Publication:	https://doi.org/10.1002/acn3.70426
PubMed:	View item in PubMed

Repository Staff Only: item control page

Download Statistics

Downloads

Downloads per month over past year